Treatment of myasthenia gravis

Focus on pyridostigmine

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Acquired myasthenia gravis (MG) is a chronic autoimmune disorder of the neuromuscular junction, characterized clinically by muscle weakness and abnormal fatigability on exertion. Current guidelines and recommendations for MG treatment are based largely on clinical experience, retrospective analyses and expert consensus. Available therapies include oral acetylcholinesterase (AChE) inhibitors for symptomatic treatment, and short- and long-term disease-modifying treatments. This review focuses on treatment of MG, mainly on the use of the AChE inhibitor pyridostigmine. Despite a lack of data from well controlled clinical trials to support their use, AChE inhibitors, of which pyridostigmine is the most commonly used, are recommended as first-line therapy for MG. Pyridostigmine has been used as a treatment for MG for over 50 years and is generally considered safe. It is suitable as a long-term treatment in patients with generalized non-progressive milder disease, and as an adjunctive therapy in patients with severe disease who are also receiving immunotherapy. Novel AChE inhibitors with oral antisense oligonucleotides have been developed and preliminary results appear to be promising. In general, however, AChE inhibitors provide only partial benefit and most patients eventually switch to long-term immunosuppressive therapies, most frequently corticosteroids andor azathioprine. Although AChE inhibitors are known to be well tolerated and effective in relieving the symptoms of MG, further efforts are required to improve treatment options for the management of this disorder.

Original languageEnglish
Pages (from-to)691-701
Number of pages11
JournalClinical Drug Investigation
Volume31
Issue number10
DOIs
Publication statusPublished - 2011

Fingerprint

Pyridostigmine Bromide
Myasthenia Gravis
Cholinesterase Inhibitors
Therapeutics
Neuromuscular Junction Diseases
Antisense Oligonucleotides
Muscle Weakness
Controlled Clinical Trials
Azathioprine
Immunosuppressive Agents
Immunotherapy
Adrenal Cortex Hormones

Keywords

  • Acetylcholinesterase-inhibitors
  • Azathioprine
  • Ciclosporin
  • Corticosteroids
  • Cyclophosphamide
  • Immunoglobulins
  • Immunosuppressants
  • Immunotherapies
  • Myasthenia-gravis
  • Mycophenolate-mofetil
  • Plasma-exchange
  • Pyridostigmine
  • Rituximab
  • Tacrolimus

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Treatment of myasthenia gravis : Focus on pyridostigmine. / Maggi, Lorenzo; Mantegazza, Renato.

In: Clinical Drug Investigation, Vol. 31, No. 10, 2011, p. 691-701.

Research output: Contribution to journalArticle

@article{f300c07971ac413ab34e4c9ca244d6b7,
title = "Treatment of myasthenia gravis: Focus on pyridostigmine",
abstract = "Acquired myasthenia gravis (MG) is a chronic autoimmune disorder of the neuromuscular junction, characterized clinically by muscle weakness and abnormal fatigability on exertion. Current guidelines and recommendations for MG treatment are based largely on clinical experience, retrospective analyses and expert consensus. Available therapies include oral acetylcholinesterase (AChE) inhibitors for symptomatic treatment, and short- and long-term disease-modifying treatments. This review focuses on treatment of MG, mainly on the use of the AChE inhibitor pyridostigmine. Despite a lack of data from well controlled clinical trials to support their use, AChE inhibitors, of which pyridostigmine is the most commonly used, are recommended as first-line therapy for MG. Pyridostigmine has been used as a treatment for MG for over 50 years and is generally considered safe. It is suitable as a long-term treatment in patients with generalized non-progressive milder disease, and as an adjunctive therapy in patients with severe disease who are also receiving immunotherapy. Novel AChE inhibitors with oral antisense oligonucleotides have been developed and preliminary results appear to be promising. In general, however, AChE inhibitors provide only partial benefit and most patients eventually switch to long-term immunosuppressive therapies, most frequently corticosteroids andor azathioprine. Although AChE inhibitors are known to be well tolerated and effective in relieving the symptoms of MG, further efforts are required to improve treatment options for the management of this disorder.",
keywords = "Acetylcholinesterase-inhibitors, Azathioprine, Ciclosporin, Corticosteroids, Cyclophosphamide, Immunoglobulins, Immunosuppressants, Immunotherapies, Myasthenia-gravis, Mycophenolate-mofetil, Plasma-exchange, Pyridostigmine, Rituximab, Tacrolimus",
author = "Lorenzo Maggi and Renato Mantegazza",
year = "2011",
doi = "10.2165/11593300-000000000-00000",
language = "English",
volume = "31",
pages = "691--701",
journal = "Clinical Drug Investigation",
issn = "1173-2563",
publisher = "Adis International Ltd",
number = "10",

}

TY - JOUR

T1 - Treatment of myasthenia gravis

T2 - Focus on pyridostigmine

AU - Maggi, Lorenzo

AU - Mantegazza, Renato

PY - 2011

Y1 - 2011

N2 - Acquired myasthenia gravis (MG) is a chronic autoimmune disorder of the neuromuscular junction, characterized clinically by muscle weakness and abnormal fatigability on exertion. Current guidelines and recommendations for MG treatment are based largely on clinical experience, retrospective analyses and expert consensus. Available therapies include oral acetylcholinesterase (AChE) inhibitors for symptomatic treatment, and short- and long-term disease-modifying treatments. This review focuses on treatment of MG, mainly on the use of the AChE inhibitor pyridostigmine. Despite a lack of data from well controlled clinical trials to support their use, AChE inhibitors, of which pyridostigmine is the most commonly used, are recommended as first-line therapy for MG. Pyridostigmine has been used as a treatment for MG for over 50 years and is generally considered safe. It is suitable as a long-term treatment in patients with generalized non-progressive milder disease, and as an adjunctive therapy in patients with severe disease who are also receiving immunotherapy. Novel AChE inhibitors with oral antisense oligonucleotides have been developed and preliminary results appear to be promising. In general, however, AChE inhibitors provide only partial benefit and most patients eventually switch to long-term immunosuppressive therapies, most frequently corticosteroids andor azathioprine. Although AChE inhibitors are known to be well tolerated and effective in relieving the symptoms of MG, further efforts are required to improve treatment options for the management of this disorder.

AB - Acquired myasthenia gravis (MG) is a chronic autoimmune disorder of the neuromuscular junction, characterized clinically by muscle weakness and abnormal fatigability on exertion. Current guidelines and recommendations for MG treatment are based largely on clinical experience, retrospective analyses and expert consensus. Available therapies include oral acetylcholinesterase (AChE) inhibitors for symptomatic treatment, and short- and long-term disease-modifying treatments. This review focuses on treatment of MG, mainly on the use of the AChE inhibitor pyridostigmine. Despite a lack of data from well controlled clinical trials to support their use, AChE inhibitors, of which pyridostigmine is the most commonly used, are recommended as first-line therapy for MG. Pyridostigmine has been used as a treatment for MG for over 50 years and is generally considered safe. It is suitable as a long-term treatment in patients with generalized non-progressive milder disease, and as an adjunctive therapy in patients with severe disease who are also receiving immunotherapy. Novel AChE inhibitors with oral antisense oligonucleotides have been developed and preliminary results appear to be promising. In general, however, AChE inhibitors provide only partial benefit and most patients eventually switch to long-term immunosuppressive therapies, most frequently corticosteroids andor azathioprine. Although AChE inhibitors are known to be well tolerated and effective in relieving the symptoms of MG, further efforts are required to improve treatment options for the management of this disorder.

KW - Acetylcholinesterase-inhibitors

KW - Azathioprine

KW - Ciclosporin

KW - Corticosteroids

KW - Cyclophosphamide

KW - Immunoglobulins

KW - Immunosuppressants

KW - Immunotherapies

KW - Myasthenia-gravis

KW - Mycophenolate-mofetil

KW - Plasma-exchange

KW - Pyridostigmine

KW - Rituximab

KW - Tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=80052441353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052441353&partnerID=8YFLogxK

U2 - 10.2165/11593300-000000000-00000

DO - 10.2165/11593300-000000000-00000

M3 - Article

VL - 31

SP - 691

EP - 701

JO - Clinical Drug Investigation

JF - Clinical Drug Investigation

SN - 1173-2563

IS - 10

ER -